The University of Chicago Header Logo

Connection

Daniel Shevrin to Male

Back to Details
This is a "connection" page, showing publications Daniel Shevrin has written about Male.
Daniel Shevrin
Connection Strength
0.286
Male
  1. Genomic predictors for treatment of late stage prostate cancer. Asian J Androl. 2016 Jul-Aug; 18(4):586-91.
    View in: PubMed
    Score: 0.028
  2. An item bank was created to improve the measurement of cancer-related fatigue. J Clin Epidemiol. 2005 Feb; 58(2):190-7.
    View in: PubMed
    Score: 0.013
  3. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Oct 01; 30(19):4318-4328.
    View in: PubMed
    Score: 0.012
  4. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19). J Clin Oncol. 2024 Apr 01; 42(10):1114-1123.
    View in: PubMed
    Score: 0.012
  5. Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). Health Qual Life Outcomes. 2003 Nov 21; 1:69.
    View in: PubMed
    Score: 0.012
  6. Correlates of thrombin generation in patients with advanced prostate cancer. Thromb Haemost. 2003 Jan; 89(1):185-9.
    View in: PubMed
    Score: 0.011
  7. Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. Prostate. 2022 09; 82(12):1176-1185.
    View in: PubMed
    Score: 0.010
  8. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559.
    View in: PubMed
    Score: 0.010
  9. Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 06; 114:107-116.
    View in: PubMed
    Score: 0.008
  10. Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncol. 2018 Mar; 14(6):527-536.
    View in: PubMed
    Score: 0.008
  11. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 04 10; 36(11):1080-1087.
    View in: PubMed
    Score: 0.008
  12. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018 04 01; 36(10):991-999.
    View in: PubMed
    Score: 0.008
  13. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 02 01; 36(4):376-382.
    View in: PubMed
    Score: 0.008
  14. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017 05; 71(5):740-747.
    View in: PubMed
    Score: 0.007
  15. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol. 2016 Dec; 12(23):2689-2699.
    View in: PubMed
    Score: 0.007
  16. Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. Urology. 2015 Dec; 86(6):1206-11.
    View in: PubMed
    Score: 0.007
  17. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 20; 373(8):737-46.
    View in: PubMed
    Score: 0.006
  18. The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther. 2015 Mar; 22(3):247-56.
    View in: PubMed
    Score: 0.006
  19. 5a-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol. 2015 Apr; 193(4):1388-93.
    View in: PubMed
    Score: 0.006
  20. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44.
    View in: PubMed
    Score: 0.006
  21. Phase II trial of 6-thioguanine in advanced renal cell carcinoma. An Illinois Cancer Center study. Invest New Drugs. 1994; 12(4):345-6.
    View in: PubMed
    Score: 0.006
  22. Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study. Invest New Drugs. 1994; 12(1):65-6.
    View in: PubMed
    Score: 0.006
  23. 5a-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. Endocrinology. 2013 Jul; 154(7):2296-307.
    View in: PubMed
    Score: 0.006
  24. Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 2014 Jan; 32(1):26.e25-31.
    View in: PubMed
    Score: 0.005
  25. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92.
    View in: PubMed
    Score: 0.005
  26. Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC-3. Prostate. 1991; 19(2):149-54.
    View in: PubMed
    Score: 0.005
  27. Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 01; 70(14):1575-85.
    View in: PubMed
    Score: 0.005
  28. Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. Psychooncology. 2011 Sep; 20(9):977-83.
    View in: PubMed
    Score: 0.005
  29. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010 Aug; 13(5):613-23.
    View in: PubMed
    Score: 0.004
  30. Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model. Prostate. 2010 Feb 01; 70(2):147-54.
    View in: PubMed
    Score: 0.004
  31. Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study. Invest New Drugs. 1989 Jul; 7(2-3):251-3.
    View in: PubMed
    Score: 0.004
  32. Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice. Prostate. 1989; 15(2):187-94.
    View in: PubMed
    Score: 0.004
  33. Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin Exp Metastasis. 1988 Sep-Oct; 6(5):401-9.
    View in: PubMed
    Score: 0.004
  34. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res. 2008 Apr 15; 14(8):2437-43.
    View in: PubMed
    Score: 0.004
  35. Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage. 2008 Jan; 35(1):20-30.
    View in: PubMed
    Score: 0.004
  36. Effect of epidermal growth factor infusion on serum and urine calcium in mice. J Bone Miner Res. 1987 Aug; 2(4):297-301.
    View in: PubMed
    Score: 0.004
  37. Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy. Support Care Cancer. 2008 Feb; 16(2):151-9.
    View in: PubMed
    Score: 0.004
  38. Phase II trial of aminothiadiazole in advanced non-small cell lung cancer. Cancer Treat Rep. 1986 Mar; 70(3):417-8.
    View in: PubMed
    Score: 0.003
  39. Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer. Lung Cancer. 2003 Feb; 39(2):221-6.
    View in: PubMed
    Score: 0.003
  40. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586). Am J Clin Oncol. 2000 Aug; 23(4):371-5.
    View in: PubMed
    Score: 0.002
  41. Assessment of coagulation system activation using spot urine measurements. Blood Coagul Fibrinolysis. 1999 Jul; 10(5):285-9.
    View in: PubMed
    Score: 0.002
  42. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer. 1993 Sep 15; 72(6):1965-8.
    View in: PubMed
    Score: 0.001
  43. In vivo and in vitro approaches to study metastasis in human prostatic cancer. Cancer Metastasis Rev. 1993 Mar; 12(1):21-8.
    View in: PubMed
    Score: 0.001
  44. Use of clonidine to treat hot flashes secondary to leuprolide or goserelin. Ann Pharmacother. 1993 Feb; 27(2):182-5.
    View in: PubMed
    Score: 0.001
  45. Analysis of gene amplification in human tumor cell lines. Proc Natl Acad Sci U S A. 1988 Sep; 85(18):6846-50.
    View in: PubMed
    Score: 0.001
  46. A model for malignancy-associated humoral hypercalcemia. Calcif Tissue Int. 1984 Sep; 36(5):563-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.